Last reviewed · How we verify
Amonafide and Cytarabine — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Amonafide and Cytarabine (Amonafide and Cytarabine) — Antisoma Research.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Amonafide and Cytarabine TARGET | Amonafide and Cytarabine | Antisoma Research | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Amonafide and Cytarabine CI watch — RSS
- Amonafide and Cytarabine CI watch — Atom
- Amonafide and Cytarabine CI watch — JSON
- Amonafide and Cytarabine alone — RSS
Cite this brief
Drug Landscape (2026). Amonafide and Cytarabine — Competitive Intelligence Brief. https://druglandscape.com/ci/amonafide-and-cytarabine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab